Processa Pharmaceuticals, Inc. (PCSA) stock

PCSANasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 5/30

$1.86+0.02 (+1.09%)

Close on Nov 13, 2026Market cap $5.20MP/E –Yield –

Processa Pharmaceuticals price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Processa Pharmaceuticals's price to sales ratio was 273.8× on Jan 31, 2017.

Period	Period end	Value	Change (pts)
2017	Jan 31, 2017	273.8×	−179.5
2016	Dec 30, 2016	453.3×	−41.0
2015	Nov 30, 2015	494.3×	–

See a number that looks wrong?